Ellagic acid alleviates ulcerative colitis in a GPR35-dependent manner associated with SDH restoration
Authors:
- 27 March 2026
- journal article
- Published by Elsevier in Phytomedicine
- Vol. 155, 158130
Abstract
No abstract availableKeywords
Funding Information
- China Postdoctoral Science Foundation (2024M763206)
- Natural Science Foundation of Jiangxi Province (20224BAB216119)
- National Natural Science Foundation of China (82304702)
- Central Asian Center of Drug Discovery and Development, Chinese Academy of Sciences (CAM202401)
This publication has 37 references indexed in Scilit:
- Ulcerative Colitis in AdultsJAMA, 2023
- Loss of Mucosal p32/gC1qR/HABP1 Triggers Energy Deficiency and Impairs Goblet Cell Differentiation in Ulcerative ColitisCellular and Molecular Gastroenterology and Hepatology, 2021
- Ellagic acid a multi-target bioactive compound for drug discovery in CNS? A narrative reviewEuropean Journal of Medicinal Chemistry, 2019
- Disruption of GPR35 Exacerbates Dextran Sulfate Sodium-Induced Colitis in MiceDigestive Diseases and Sciences, 2018
- Discovery and Optimization of an Azetidine Chemical Series As a Free Fatty Acid Receptor 2 (FFA2) Antagonist: From Hit to ClinicJournal of Medicinal Chemistry, 2014
- Mitochondrial electron transport chain complex dysfunction in the colonic mucosa in ulcerative colitisInflammatory Bowel Diseases, 2012
- Protective effect of ellagic acid, a natural polyphenolic compound, in a murine model of Crohn's diseaseBiochemical Pharmacology, 2011
- Mitochondrial respiratory chain in the colonic mucosal of patients with ulcerative colitisMolecular and Cellular Biochemistry, 2010
- Ellagic acid inhibits lipopolysaccharide-induced expression of enzymes involved in the synthesis of prostaglandin E2in human monocytesBritish Journal of Nutrition, 2009
- Comparative proteomic studies on the pathogenesis of human ulcerative colitisProteomics, 2006